Philogen S.p.A.'s latest marketcap:
As of 06/06/2025, Philogen S.p.A.'s market capitalization has reached $1.03 B. According to our data, Philogen S.p.A. is the 9270th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.03 B |
| Revenue (ttm) | 88.43 M |
| Net Income (ttm) | 51.58 M |
| Shares Out | 40.33 M |
| EPS (ttm) | 1.28 |
| Forward PE | 10.28 |
| Ex-Dividend Date | n/a |
| Earnings Date | 09/23/2025 |
Philogen S.p.A.'s yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/06/2025 | €903.44 M | 14.99% |
| 12/30/2024 | €785.65 M | 5.33% |
| 12/29/2023 | €745.86 M | 30.99% |
| 12/30/2022 | €569.38 M | -2.2% |
| 12/30/2021 | €582.19 M |
Company Profile
About Philogen S.p.A.
Philogen S.p.A. is a biotechnology company specializing in the development of innovative drugs for oncology and chronic inflammatory diseases. Founded in 1996 and headquartered in Siena, Italy, the company focuses on cutting-edge therapies to address unmet medical needs.
Key Pipeline Products
- Nidlegy – A combination of immunocytokines L19IL2 and L19TNF for intralesional treatment of locoregional melanoma and non-melanoma skin cancers.
- Fibromun – An immunomodulatory product (L19 antibody + TNF) targeting soft tissue sarcoma, leiomyosarcoma, and glioma.
- Darleukin (L19IL2) – An immunostimulatory product (L19 antibody + IL2) in Phase II trials for non-small cell lung cancer.
- Dodekin – A vascular-targeting antibody fused to interleukin-12 in Phase I/II trials for advanced solid tumors.
- Dekavil (F8IL10) – An anti-inflammatory product in Phase II trials for chronic inflammatory disorders.
- Onco IX (PHC-102) – A radiotracer for detecting CAIX-expressing solid tumors in Phase I trials.
- OncoFAP – A radiotracer targeting fibroblast activation protein in metastatic solid tumors (Phase I).
- Tripokin – A preclinical-stage immunostimulatory product combining TNF and IL-2.
Philogen’s pipeline reflects its commitment to advancing novel therapies through clinical development, with a strong focus on precision medicine and targeted treatments.
Frequently Asked Questions
-
What is Philogen S.p.A.'s (BIT-PHIL) current market cap?As of 06/06/2025, Philogen S.p.A. (including the parent company, if applicable) has an estimated market capitalization of $1.03 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Philogen S.p.A. (BIT-PHIL) rank globally by market cap?Philogen S.p.A. global market capitalization ranking is approximately 9270 as of 06/06/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.